Cytiva acquires Cevec Pharmaceuticals to boost cell line development

By The Science Advisory Board staff writers

October 10, 2022 -- Life sciences company Cytiva has acquired Cevec Pharmaceuticals, a German provider of high-performance cell line development and viral vector manufacturing technologies, for an undisclosed amount. The deal will further strengthen Cytiva's cell line development, according to the companies.

One of the pharmaceutical industry's biggest challenges in cell and gene therapy is establishing production processes that can keep up with the increasing demand for volume and consistent quality of viral vectors. With its scalable producer cell lines for vectors based on adeno- associated virus (AAV) and adenovirus, Cevec covers two of the most widely used vectors for delivering therapeutic genes to target cells and tissues.

Viral vectors are altered viruses that can safely transport therapeutic products into cells. Adenoviruses are DNA viruses with broad cell tropism that can transiently transduce nearly any mammalian cell type. AAVs are capable of transducing a broad range of dividing and non- dividing cell types, but they require coinfection with a helper virus like adenovirus or herpes virus to produce recombinant virions in packaging cells.

"Cevec's innovative technology complements Cytiva's offering and brings the promise of improved viral vector manufacturing," Emmanuel Abate, president of genomic medicine at Cytiva, said in a statement.

The acquisition will allow customers to have immediate access to Cevec's technology and expertise to help accelerate and advance gene therapies for the benefit of patients. In addition, 46 scientific experts based in Cologne, Germany will join the Cytiva team in the genomic medicine space.

Cytiva works with academic and translational researchers, developers, and manufacturers of biotherapeutics, cell and gene therapies, as well as new technologies such as mRNA, to enable the delivery of transformative medicines.

A recent report in Cell and Gene Therapy Business Outlook (CGTBO), a sister publication of ScienceBoard, found that the industry needs 2 to 3 billion liters of bioreactor capacity to meet the current demand for viral vectors. However, production cannot keep up with demand.

"Future needs will require about 5-6 million liters of bioreactor capacity per year. Change is needed for both upstream and downstream development, and a streamlined process would be desirable," states the CGTBO report.

How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...
Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors
It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors,...
Focus on drug-manufacturing optimization prioritizes patient health
As medical innovations and therapeutics advance rapidly and dramatically increase in scale, there is a critical need for manufacturing processes that...
Cytiva triples single-use consumables capacity in China
Cytiva has tripled its capacity for single-use consumables in China with the help of three new manufacturing lines, the company said.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter